Ocular melanoma is a malignant tumor that originates from melanocytes, which are responsible for synthesizing the pigment melanin. The most common form of ocular melanoma is choroidal melanoma, which occurs in the vascular layer of the eye located under the retina. Ocular melanoma can lead to serious consequences, including vision loss and metastasis to other organs, which significantly worsens the prognosis for the patient. Since the disease is asymptomatic in the early stages, its diagnosis is often delayed, which emphasizes the importance of regular examinations by an ophthalmologist, especially in patients with a predisposition to this disease.
History of the disease and interesting historical facts
The history of melanoma of the eye has evolved over many centuries. The first mention of melanoma dates back to the ancient Greek physician Hippocrates, who described tumors with a dark pigment. However, real advances in understanding and treating this disease did not begin until the 19th century, when doctors began systematically studying the natural properties and behavior of tumors. In 1906, Austrian pathologist Gustav Runge took the first steps toward classifying tumors, including melanoma, distinguishing it from other types of neoplasms.
Since the mid-20th century, active work has been underway to study the genetic aspects of melanoma, which has made it possible to identify predisposing factors and improve diagnostics. In the 20th century, the use of imaging technologies such as ultrasound diagnostics and fluorescent angiography has significantly improved the early detection of ocular melanoma. Today, the influence of various factors on the development and course of the disease, as well as new methods of treatment and monitoring of patients, are being studied.
Epidemiology
The incidence of ocular melanoma varies by region and population. According to the American Cancer Society, ocular melanoma occurs in approximately 5 to 7 people per million population per year. Epidemiological studies show that the disease is more common in people with lighter skin, especially those with red or blond hair and blue eyes. Melanoma is also associated with long-term exposure of the eyes to ultraviolet radiation from the sun.
Some studies report that the risk of developing ocular melanoma increases with age, with an increase in incidence among people over 50 years of age. Gender also plays a role: men are 1.5-2 times more likely to develop the disease than women. The prognosis for melanoma of the face and body differs significantly: survival after 5 years is about 80-90% in the case of localized forms, but significantly decreases in the presence of metastases.
Genetic predisposition to this disease
Genetic predisposition to ocular melanoma is quite complex, involving various genes and mutations. The most well-known of these genes include BRAF, NRAS, and KIT. Mutations in the BRAF gene, especially V600E, are observed in approximately 40-60% melanoma patients. This discovery was an important step in the development of targeted therapies aimed at blocking the excess activity of this gene.
In addition, polymorphisms in genes associated with vitamin D metabolism and other carcinogenic factors may also play a role in predisposition to this disease. Familial cases of melanoma indicate the importance of genetic factors, and every year the number of studies aimed at identifying new predisposing mutations and polymorphisms increases.
Risk factors for the development of this disease
Among the risk factors that contribute to the development of melanoma of the eye, several groups are distinguished:
- Physical factors:
- Long-term exposure to ultraviolet radiation, especially at an early age.
- Having fair skin, as well as red or blond hair and blue eyes.
- Chemical factors:
- Exposure to certain chemicals, such as hair dyes, some pesticides, and sunscreens that contain high levels of chemicals.
- Other factors:
- History of cutaneous melanoma or family history of this disease.
- Immunodeficiency states, including HIV infection or after organ transplantation.
- Presence of moles or nevi on the eyes.
Diagnosis of this disease
Diagnosis of melanoma of the eye includes a comprehensive examination and the use of various methods:
- Main symptoms:
- Change in color or size of a mole on the eye.
- Loss of vision or blurriness.
- The presence of new pigment formations on the eye.
- Laboratory tests:
- Histological examination of tissue samples to determine the presence of malignant cells.
- Determination of tumor markers in the blood.
- Radiological examinations:
- Ultrasound diagnostics to assess the size and nature of the tumor.
- Magnetic resonance imaging (MRI) to detect metastases.
- Other types of disease diagnostics:
- Fluorescein angiography to assess the vascular nature of the tumor.
- Optical coherence tomography (OCT) for a more detailed study of the structure of the eye.
- Differential diagnosis:
- Neoplasms such as lymphoma and bronchogenic carcinoma.
- Other pigmented lesions on the eyes, including nevi and hemangiomas.
Treatment
Treatment for ocular melanoma is determined by the stage of the disease and may include the following approaches:
- General treatment:
- Chemotherapy is used for metastatic disease, although the effect may be limited.
- Immunotherapy using checkpoint inhibitors such as anti-PD-1 has shown encouraging results.
- Pharmacological treatment:
- Targeted therapy based on BRAF and MEK inhibitors for patients with active mutations.
- Surgical treatment:
- Removal of the tumor while preserving the maximum portion of the organ.
- Enucleation of the eye in cases where melanoma has progressed significantly.
- Other types of treatment:
- Radiation therapy, including radiotherapy and stereotactic radiotherapy.
- Intraocular radiotherapy to shrink the tumor.
List of medications used to treat this disease
There are several classes of drugs used to treat ocular melanoma:
- BRAF inhibitors:
- Dabrafenib.
- Vemurafenib.
- MEK inhibitors:
- Trametinib.
- PD-1 inhibitors:
- Pembrolizumab.
- Nivolumab.
Disease monitoring
Monitoring the patient's condition after treatment for ocular melanoma is critical to prevent recurrence and detect metastases. Regular eye exams include:
- Control stages:
- Examination every 3-6 months during the first year after treatment.
- Conducting ultrasound examination and MRI as needed.
- Forecast:
- The prognosis depends on the stage of the disease - in the early stages, 5-year survival can reach 80-90%.
- In the presence of metastases, the prognosis worsens significantly.
- Complications:
- Loss of vision due to tumor growth.
- Systemic complications due to metastatic disease.
Age-related features of the disease
Ocular melanoma can occur in different age groups, but it is most often seen in people over 50 years of age.
- In children and adolescents:
- Ocular melanoma is extremely rare in this group, but the presence of cutaneous melanoma may indicate a predisposition.
- In adults:
- Most often, the disease is diagnosed in people aged 50-70 years.
- Genetic factors and long-term sun exposure significantly influence the occurrence of the disease in this group.
- In the elderly:
- The risk of developing melanoma increases with age, which is associated with the accumulation of predispositions and risk factors throughout life.
Questions and Answers
- What is ocular melanoma? Ocular melanoma is a malignant tumor that arises from melanocytes, which can lead to vision loss and metastasis.
- Who is at risk for developing ocular melanoma? The main risk factors are fair skin, prolonged sun exposure, family history and the presence of certain genetic mutations.
- What are the main symptoms of ocular melanoma? The main symptoms include changes in moles, blurred vision, the appearance of new pigmented lesions, and eye inflammation.
- How is ocular melanoma diagnosed? Diagnosis includes examination by an ophthalmologist, ultrasound examination and, if necessary, MRI or histological examination.
- What is the treatment for ocular melanoma? Treatment may include surgical removal of the tumor, targeted therapy, immunotherapy, and radiation therapy.
